Irsogladine

Synonyms: 伊索拉定; Dicloguamine
Irsogladine(Dicloguamine)是一种具有口服活性的胃黏膜保护剂,可抑制裸鼠乳腺癌复发及肺转移,抑制 NF-κB 和 AP-1 的转录活性,抑制 PDE 和 PDE4 的活性以升高细胞内 cAMP 水平,并激活 TRPV1 和 KATP 通道,增强 iNOS 表达、NO 生成以及环磷酸腺苷应答元件的激活,抑制 Apc 突变小鼠肠道息肉的发生发展,减轻氧化应激、增加胃黏膜血流量并刺激内源性前列腺素的生成,促进 MIN6 细胞分泌胰岛素,抑制肿瘤血管生成、癌细胞增殖以及促炎细胞因子的产生,对乙醇/盐酸诱导的小鼠胃溃疡的星形细胞具有保护作用,通过降低 IL-12 和 IL-23 的生成预防 IL-10 基因缺陷小鼠发生结肠炎,通过 PKA 通路上调胰腺癌细胞间的间隙连接细胞间通讯,并可用于乳腺癌、肠息肉病、胃溃疡、自发性结肠炎、胶质瘤、肝癌和胰腺癌的相关研究。
产品编号: MS-C38443 纯度: 99.88% CAS No.: 57381-26-7 分子式: C9H7Cl2N5 分子量: 256.09
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
500mg
询价
3-5 天
1g
询价
询价
5g
询价
询价
(0.1 - 0.2mg)
询价
询价

产品描述

Irsogladine(Dicloguamine)是一种具有口服活性的胃黏膜保护剂,可抑制裸鼠乳腺癌复发及肺转移,抑制 NF-κB 和 AP-1 的转录活性,抑制 PDE 和 PDE4 的活性以升高细胞内 cAMP 水平,并激活 TRPV1 和 KATP 通道,增强 iNOS 表达、NO 生成以及环磷酸腺苷应答元件的激活,抑制 Apc 突变小鼠肠道息肉的发生发展,减轻氧化应激、增加胃黏膜血流量并刺激内源性前列腺素的生成,促进 MIN6 细胞分泌胰岛素,抑制肿瘤血管生成、癌细胞增殖以及促炎细胞因子的产生,对乙醇/盐酸诱导的小鼠胃溃疡的星形细胞具有保护作用,通过降低 IL-12 和 IL-23 的生成预防 IL-10 基因缺陷小鼠发生结肠炎,通过 PKA 通路上调胰腺癌细胞间的间隙连接细胞间通讯,并可用于乳腺癌、肠息肉病、胃溃疡、自发性结肠炎、胶质瘤、肝癌和胰腺癌的相关研究。

生物实验数据

生物活性 Irsogladine (Dicloguamine) is an orally active gastric mucosal protective agent that inhibits breast cancer recurrence and lung metastasis in nude mice, suppresses the transcriptional activity of NF-κB and AP-1, inhibits PDE and PDE4 activity to elevate intracellular cAMP levels, and activates TRPV1 and KATP channels, enhances iNOS expression, NO production, and activation of the cAMP response element, inhibits the initiation and progression of intestinal polyps in Apc-mutant mice, alleviates oxidative stress, increases gastric mucosal blood flow, and stimulates endogenous prostaglandin production, promotes insulin secretion in MIN6 cells, inhibits tumor angiogenesis, cancer cell proliferation, and pro-inflammatory cytokine production, exerts a protective effect on astrocytes in ethanol/HCl-induced gastric ulcers in mice, prevents colitis in IL-10 gene-deficient mice by reducing IL-12 and IL-23 production, upregulates gap junction intercellular communication between pancreatic cancer cells via the PKA pathway, and can be used for research related to breast cancer, intestinal polyposis, gastric ulcers, spontaneous colitis, glioma, liver cancer, and pancreatic cancer.
IC50 & Target

PDE4

 

体外研究
(In Vitro)

Irsogladine (1-100 μM; 48 h) 在 100 μM 浓度下可将 HUVEC 和 MDA-MB-435 细胞的增殖抑制 15%。
Irsogladine (100-200 μM; 24-48 h) maleate 可抑制 Caco-2 细胞中 AP-1 和 NF-κB 的转录活性。
Irsogladine (100-200 μM; 24 h) maleate 可抑制 HCT-15 细胞中基础 NF-κB 的转录活性。
Irsogladine (1-10 μM; 24 h) 显著增强 NO 供体 SNAP 和 NONOate 对肾小球系膜细胞的抗增殖作用。
Irsogladine (10 μM; 24 h) 可轻度上调大鼠肾小球系膜细胞中连接蛋白 43 的表达,并能显著增强 SNAP (MS-P26969) 诱导的细胞中连接蛋白 43 的表达升高。
Irsogladine (10 μM; 1 h) 可使大鼠肾小球系膜细胞内的 cAMP 水平出现小幅显著升高,且与 SNAP 联合作用于该细胞时可协同提升 cAMP 水平。
Irsogladine (10 μM; 1 h) 可在大鼠肾小球系膜细胞中微弱激活 PKA,并能强效增强该细胞中 SNAP 诱导的 PKA 激活。
Irsogladine (0.1-100 μM; 24 h) 在大鼠肾小球系膜细胞中与 NO 供体 (SNAP、SNP (MS-S52919)、NONOate) 或细胞因子诱导的内源性 NO 联合使用时,可协同激活 CRE。
Irsogladine (10 μM; 24 h) 与 sGC 激活剂 Bay 41-2272 (MS-F57770) 或 PDE3 相互作用型 cGMP 类似物 8-bromo-cGMP (MS-X42218 ) 联用时,可在大鼠肾小球系膜细胞中协同激活 CRE 和 PKA。
Irsogladine (10 μM; 24 h) 在大鼠肾小球系膜细胞中显著增强细胞因子 (TNF-α + IL-1β) 诱导的上述细胞中 iNOS 的表达及 NO 的生成。
Irsogladine (1.0×10-8-1.0×10-5 M; 30 min pre-incubation, 60 min co-incubation with glucose) 当浓度为 1.0×10-5 M 时可使胰岛素分泌增加 1.7 倍,该效应依赖于功能性缝隙连接和 cAMP-PKA 通路。
Irsogladine (1.0×10-5 M; 30 min) 在 MIN6 细胞中提高质膜相关 Cx36 蛋白水平、cAMP 水平表达。
Irsogladine (10-7-10-4 M; 24 h) 可剂量依赖性地抑制 J774A.1 小鼠单核/巨噬细胞中 IL-12p40 和 IL-23p19 的基因表达与蛋白分泌,抑制 IL-23 分泌,降低 TNF-α mRNA 表达。
Irsogladine (10-6-10-4 M; 5 days) 可特异性抑制人微血管内皮细胞和人脐静脉内皮细胞的增殖。
Irsogladine (10-6-10-4 M; 3 days) 抑制 U251 诱导的人微血管内皮细胞管形成。
Irsogladine malate (10-6 M; 3-5 days until 90-95% confluence) 可显著上调人胰腺癌细胞 PANC-1 之间的 GJIC。
Irsogladine malate (10-8-10-6 M; 3-5 days until 90-95% confluence) 可呈剂量依赖性地升高人胰腺癌细胞 PANC-1 膜组分中磷酸化 Cx43 (P1、P2) 的水平。
Irsogladine malate (10-6 M; 3-5 days until 90-95% confluence) 可诱导人胰腺癌细胞 PANC-1 中 Cx43 蛋白从细胞质重新定位至细胞间边界。
Irsogladine malate (10-6 M; 3-5 days until 90-95% confluence) 可使 PANC-1 人胰腺癌细胞内的 cAMP 水平显著升高。

Cell Proliferation Assay

Cell Line: HUVEC cells, MDA-MB-435 cells
Concentration: 1 μM; 10 μM; 100 μM
Incubation Time: 48 h
Result: Inhibited the proliferation of HUVEC and MDA-MB-435 cells by 15% at 100 μM.
Had no effect on proliferation of either cell line at 1 μM and 10 μM.

Cell Proliferation Assay

Cell Line: rat glomerular mesangial cells (SM43 line)
Concentration: 1 μM, 10 μM
Incubation Time: 24 h
Result: Did not affect PDGF-induced mesangial cell proliferation at 10 μM.
Significantly potentiated the anti-proliferative effect of the NO donor SNAP at 1 μM.
Potentiated the anti-proliferative effect of the NO donor NONOate at 1 μM.
Showed no cytotoxic effects at 1, 10 μM when evaluated by LDH release.

Western Blot Analysis

Cell Line: rat glomerular mesangial cells
Concentration: 10 μM
Incubation Time: 24 h
Result: Modestly elevated Cx43 expression in mesangial cells when used alone.
Greatly potentiated the concentration-dependent SNAP-induced elevation of Cx43 levels when combined with SNAP (1, 10, 100 μM).

Western Blot Analysis

Cell Line: rat glomerular mesangial cells
Concentration: 10 μM
Incubation Time: 1 h
Result: Induced a slight increase in VASP serine 157 phosphorylation when used alone.
Potently induced VASP serine 157 phosphorylation, reflecting strong PKA activation, when combined with 100 μM SNAP.

ELISA Assay

Cell Line: mouse insulin-secreting MIN6 cells
Concentration: 1.0×10-8 M, 1.0×10-7 M, 1.0×10-6 M, 1.0×10-5 M
Incubation Time: 30 min (pre-incubation); 60 min (co-incubation with glucose)
Result: Had no effect on insulin secretion under 5.6 mM glucose conditions.
Induced a 1.7 fold increase in insulin secretion compared to control under 16.8 mM glucose conditions.
Showed this insulin secretion-inducing effect was inhibited by co-treatment with a gap junction inhibitor, pre-treatment with Rp-cAMP, or co-treatment with H89.

Cell Proliferation Assay

Cell Line: human microvascular endothelial cells, human umbilical endothelial cells, human glioma U251 cells, human epidermoid cancer KB cells
Concentration: 10-6 M, 10-5 M, 10-4 M
Incubation Time: 5 days
Result: Inhibited the proliferation of human microvascular endothelial cells and human umbilical endothelial cells by >30% of control levels.
Did not affect the proliferation of human glioma U251 cells or human epidermoid cancer KB cells.

Immunofluorescence

Cell Line: PANC-1 human pancreatic cancer cells
Concentration: 10-6 M
Incubation Time: 3-5 days (until 90-95% confluence)
Result: Induced Cx43 immunofluorescence to appear as large spots or short lines at the boundaries between adjacent cells, indicating relocalization from the cytoplasm (particularly perinuclear regions in untreated cells) to cell-cell junctions.
Had this relocalization inhibited by co-treatment with H-89 or SQ22536.

ELISA Assay

Cell Line: PANC-1 human pancreatic cancer cells
Concentration: 10-6 M
Incubation Time: 3-5 days (until 90-95% confluence)
Result: Increased intracellular cAMP levels by approximately fivefold relative to untreated controls.
Showed a significant increase.
体内研究
(In Vivo)

Irsogladine (120 mg/kg,灌胃,每日 1 次,连续 5 周) 可使接受肿瘤切除的 MDA-MB-435 异种移植裸鼠的乳腺肿瘤复发率降低 39.6%,肺转移体积减少 48.4%,肺转移灶数量减少 63.9%,且不会改变小鼠体重。
Irsogladine (5-50 ppm;饲料给药;自由摄取;8 周) maleate 抑制雄性 Min 小鼠的肠道息肉形成 (分别使息肉总数降至对照组的 69.3%和 66.1%),其作用机制部分为抑制 NF-κB 信号通路并减少氧化应激相关的活性羰基物种。
Irsogladine maleate (饮食自由摄取,持续 25 周) 可抑制经 N-甲基-N’-硝基-N-亚硝基胍启动、乙二醛促进胃癌发生的雄性 Wistar 大鼠的消化道肿瘤发展。
Irsogladine maleate (125 ppm;饲料给药;自由摄取;35 周) 可完全抑制经二乙基亚硝胺启动、苯巴比妥促癌的雄性 F344 大鼠的肝脏肿瘤发生 (发生率为 0%)。
Irsogladine (1-10 mg/kg;口服;单次给药;溃疡诱导前 1 小时) 在雄性 ICR 小鼠中对乙醇/盐酸诱导的胃溃疡表现出剂量依赖性的胃保护作用,在 10 mg/kg 剂量下的损伤抑制率达 84.2%,其作用部分由 cAMP 水平升高、前列腺素活性增强、KATP 通道开放及抗氧化特性介导。
Irsogladine (100 ppm;口服;每日;连续 10 周) 可通过将结肠组织学评分降至 1.6,并通过抑制 IL-12 和 IL-23 的产生来抑制 Th1/Th17 通路的细胞因子表达,从而预防 IL-10−/−小鼠的自发性结肠炎。
Irsogladine (30-120 mg/kg;口服;每日;连续 4 周) 可剂量依赖性地抑制 BALB/c nu/nu 小鼠的胶质瘤肿瘤生长并降低肿瘤微血管密度,其中 60 mg/kg/天的剂量可使肿瘤体积减少约 50%,120 mg/kg/天的剂量可使微血管计数降至对照组水平的约 30%。
Irsogladine (30-60 mg/kg;口服;每日;连续 7 天) 可抑制小鼠背侧气囊中肝癌诱导的肿瘤新生血管形成,其中 60 mg/kg/天的剂量可完全阻止肿瘤特异性新生血管的形成,且不会影响已存在的血管。

Animal Model: BALB/c nude (female, 6-8 weeks old, human MDA-MB-435 breast cancer cell mammary fat pad injection model)
Dosage: 120 mg/kg
Administration: p.o.; daily; 5 weeks
Result: Inhibited primary tumor regrowth by 39.6%.
Reduced pulmonary metastasis incidence, with 31% of treated mice free of pulmonary metastases.
Inhibited mean volume of pulmonary metastases by 48.4%.
Did not affect mouse body weight.
Animal Model: C57BL/6-ApcMin/+ (male, 5 weeks of age)
Dosage: 5 ppm; 50 ppm
Administration: dietary; ad libitum; 8 weeks
Result: Reduced total intestinal polyp number to 69.3% of control, proximal small intestine polyps to 61.5% of control, distal small intestine polyps to 21.9% of control, polyps <0.5 mm and 1.5-2.0 mm in diameter, serum triglyceride levels to 42.1% of control, and suppressed IL-1β mRNA levels in polyps to 85% of control, IL-6 mRNA levels in polyps to 51% of control, and reduced levels of 194 hepatic reactive carbonyl species peaks, and significantly reduced levels of specific reactive carbonyl species including acetaldehyde, acrolein, pentanal, hexanal, 2,4-NDE, 2-nonenal, HNE, decanal, undecanal, dodecanal, tridecanal, tetradecanal, hexadecanal, 8-HpDE, and heptadecanal at 5 ppm.
Reduced total intestinal polyp number to 66.1% of control, proximal small intestine polyps to 53.8% of control, middle small intestine polyps to 39.7% of control, polyps <0.5 mm and 0.5-1.0 mm in diameter, serum triglyceride levels to 73.4% of control, and reduced levels of 163 hepatic reactive carbonyl species peaks, and significantly reduced levels of specific reactive carbonyl species including acrolein, pentanal, 2-hexenal, hexanal, 2,4-NDE, 2-nonenal, HNE, tetradecanal, hexadecanal, and heptadecanal at 50 ppm.
Did not affect body weight, food intake, clinical signs, organ weights, gastric histopathology, serum free fatty acid or total cholesterol levels, and only slightly reduced PCNA-positive cell percentage in polyps (not statistically significant) at both doses.
Animal Model: F344 (male)
Dosage: 125 ppm
Administration: dietary; ad libitum; 35 weeks
Result: Prevented the development of liver neoplasms, with an incidence of 0/14 rats.
Animal Model: ICR (male, 25-30 g)
Dosage: 1 mg/kg; 10 mg/kg
Administration: p.o.; single dose; 1 hour before ulcer induction
Result: Reduced gastric mucosal injury area to 7.86 mm2, achieving 15.0% inhibition of ethanol/HCl-induced lesions compared to vehicle.
Showed slight reduction of gastric mucosal damage via histological analysis.
Reduced gastric mucosal injury area to 1.42 mm2, achieving 84.2% inhibition of ethanol/HCl-induced lesions compared to vehicle.
Showed near-restoration of normal gastric mucosa via histological analysis.
Increased gastric mucosal cAMP levels to 5.8 pmol/mg protein (165% of vehicle levels); when combined with S-nitroso acetyl penicillamine, cAMP levels synergistically increased to 8.3 pmol/mg protein (243% of vehicle levels).
Reduced ethanol/HCl-induced mucosal lesions to 8.4% of total gastric size; this effect was slightly reversed by the K_ATP channel blocker glibenclamide, and slightly reduced by the TRPV1 antagonist capsazepine and cyclooxygenase inhibitor indomethacin.
Reduced thiobarbituric acid reactive substances (TBARS) levels to 40.5 nM/g tissue at 1 mg/kg; reduced TBARS levels to 28.9 nM/g tissue at 10 mg/kg, indicating inhibition of lipid peroxidation.
Animal Model: IL-10−/− (5 weeks old, gender ratio balanced)
Dosage: 100 ppm
Administration: oral; daily; 10 consecutive weeks
Result: Increased mean colon length significantly.
Reduced mean colon weight significantly.
Reduced mean histological colitis score from 3.8 to 1.6.
Suppressed colonic tissue mRNA expression of proinflammatory cytokines: TNF-α (-2.5-fold), IL-1β (-5.4-fold), IFN-γ (-4.5-fold), IL-17 (-113.0-fold), IL-12p35 (-21.0-fold), IL-12p40 (-3.4-fold), and IL-23p19 (-4.2-fold) relative to controls.
Showed no significant difference in body weight gain compared to controls over the 10-week period.
Reduced colonic wall thickening and redness compared to controls.
Animal Model: BALB/c nu/nu (male, 5 weeks old, ~20 g, subcutaneous implantation of human glioma U251 cells)
Dosage: 30 mg/kg; 60 mg/kg; 120 mg/kg
Administration: p.o.; daily; 4 weeks
Result: Reduced average tumor volume to ~50% of control at 60 mg/kg/day, with greater reduction at 120 mg/kg/day.
Reduced factor VIII-positive microvessels per ×100 field to ~95 at 30 mg/kg/day, ~60 at 60 mg/kg/day, and ~35 at 120 mg/kg/day (control ~115).
Did not affect mouse body weight at any dose.
Animal Model: (implantation of diffusion chambers with human hepatic cancer HepG2 cells into dorsal air sacs)
Dosage: 30 mg/kg; 60 mg/kg
Administration: p.o.; daily; 7 days
Result: Reduced the development of HepG2-induced tumor neovasculatures, with only short neovasculatures observed at 30 mg/kg/day.
Almost completely eliminated the appearance of HepG2-induced tumor neovasculatures at 60 mg/kg/day.
Did not affect preexisting blood vessels at 60 mg/kg/day.
性状 固体
颜色 White to off-white

化学信息

分子量 256.09
分子式 C9H7Cl2N5
CAS No. 57381-26-7
别名 伊索拉定; Dicloguamine

储存&溶解度

体内实验配方
10% DMSO+90% Corn Oil: 3.3 mg/mL (12.89 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 120 mg/mL (468.59 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

H2O 中的溶解度 : < 0.1 mg/mL (insoluble)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.9049 mL19.5244 mL39.0488 mL97.6219 mL
5 mM0.7810 mL3.9049 mL7.8098 mL19.5244 mL
10 mM0.3905 mL1.9524 mL3.9049 mL9.7622 mL
15 mM0.2603 mL1.3016 mL2.6033 mL6.5081 mL
20 mM0.1952 mL0.9762 mL1.9524 mL4.8811 mL
25 mM0.1562 mL0.7810 mL1.5620 mL3.9049 mL
30 mM0.1302 mL0.6508 mL1.3016 mL3.2541 mL
40 mM0.0976 mL0.4881 mL0.9762 mL2.4405 mL
50 mM0.0781 mL0.3905 mL0.7810 mL1.9524 mL
60 mM0.0651 mL0.3254 mL0.6508 mL1.6270 mL
80 mM0.0488 mL0.2441 mL0.4881 mL1.2203 mL
100 mM0.0390 mL0.1952 mL0.3905 mL0.9762 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础